GlipiZIDE Extended-release tablets — Class II drug recall D-0520-2017
Terminated recall by Amerisource Health Services, reported 2017-03-22, distributed nationwide. Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for th
| Recall number | D-0520-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Amerisource Health Services, Columbus, OH, United States |
| Recall initiated | 2017-02-03 |
| Classified | 2017-03-14 |
| Reported by FDA | 2017-03-22 |
| Terminated | 2018-03-01 |
| Distributed | Nationwide (US) |
| Reason classes | specification failure |
| NDC | 68084-0295-21, 68084-0395-11 |
| Lot numbers | 08/17, 09/17, 10/17, 160133, 160549, 162006, 163348A, 163348B |
Product
GlipiZIDE Extended-release tablets, 2.5 mg, 30-count carton (NDC 68084-295-21), Individual dose (NDC 68084-395-11), Rx Only, Packaged and Distributed by American Health Packaging, Columbus, Ohio 43217, NDC 68084-295-21
Reason for recall
Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0520-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.